Millennium Prostate Cancer Agent Selected For FDA Continuous Marketing Application Pilot
This article was originally published in The Pink Sheet Daily
Executive Summary
The monoclonal antibody-linked chemotherapeutic MLN2704 is in a Phase I/II study for metastatic androgen-independent prostate cancer.
You may also be interested in...
FDA’s Second Continuous Marketing Application Pilot Program Nearly 50% Enrolled
Nine divisions have not yet selected their application for the pilot program, which involves frequent scientific feedback and interactions with FDA during the IND phase of product development. Applications are being accepted through the end of September.
HGS Lymphostat-B Is One Of Seven Agents Selected For CDER Continuous Marketing Pilot 2
Participation in the Pilot 2 continuous marketing application program is limited to one fast-track product per reviewing division. Human Genome Sciences’ belimumab has entered a year-long Phase II study in 350 patients with systemic lupus erythematosus.
FTC Suffers Reversal On “Reverse Payments” Enforcement
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.